Andere talen Genscript Biotech Corporation

Aandelen

1548

KYG3825B1059

Beurs gesloten - Hong Kong S.E. Andere beurzen 10:08:15 18-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
11,46 ^HKD	-0,35%		-12,25%	-42,30%

12/04	Genscript Biotech Corporation kondigt directeursbenoemingen en verandering in samenstelling van bestuurscommissie aan	CI
09/04	Refractaire multiple myeloommedicijn van Genscript Biotech-afdeling krijgt goedkeuring van FDA	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Genscript Biotech's Unit Logs $157 Million in Q1 Sales of Blood Cancer Drug	17/04
GenScript Biotech officially joins SBTi to fulfill its sustainability commitment	16/04
Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee	12/04
Genscript Biotech Unit's Refractory Multiple Myeloma Drug Gets FDA Approval	09/04
GenScript Biotech Receives EcoVadis Bronze Medal for Outstanding Sustainability Performance	27/03
Genscript Biotech's US Unit Secures FDA Nod for Anti-Cancer Medication	19/03
Genscript Biotech Issues 444,598 Shares to Three Grantees Under Restricted Share Scheme	14/03
Genscript Biotech's 2023 Loss Widens; Misses Revenue Estimates	11/03
Genscript Biotech Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	10/03
Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board	08/03
Immunotherapy Pioneer Carl H. June, MD, Joins GenScript's Scientific Advisory Board to Guide Company's Innovation Strategy in Advancing Cell and Gene Therapy Breakthroughs	06/03
GenScript Biotech Corporation Expands Collaboration with Roche	05/03
GenScript Announces Its Inaugural Life Science Research Grant Project	05/02
Genscript Biotech Unit Rakes in $159 Million in Sales for Myeloma Treatment; Shares Rise 4%	24/01
Genscript Biotech Unit to Submit More Data to European, US Authorities for Approval of Myeloma Drug	24/01
San Francisco Witnesses the Voice of GCT Titans GenScript Biotech Global Forum Outlines the Future of the Industry	12/01
Genscript, Legend Biotech On-Track to Begin Production at Ghent Facilities This Year	10/01
Genscript Biotech's Subsidiary Legend Closes License Agreement with Novartis for Anti-Cancer Drug	04/01
GenScript, GenScript ProBio, and Legend Biotech Will Attend the 42nd JPM Healthcare Conference, Advancing Innovation and Development in the Healthcare Sector	04/01
GenScript Biotech Global Forum 2024 to Commence, Infusing New Vitality into the GCT Industry	04/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Genscript Biotech Corporation

Aandelen

1548

KYG3825B1059

Andere talen

Filters